Previous 10 | Next 10 |
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 17-19, 2021. Ron Rocca, Exag...
Gainers: [[TGC]] +29.7%. [[FLDM]] +17.7%. [[SWIR]] +13%. [[XGN]] +12%. [[RNWK]] +6.8%.Losers: [[PGEN]] -8.3%. [[USX]] -7.9%. [[GSL]] -7.4%. [[CTK]] -7%. [[RUHN]] -6.4%. For further details see: SWIR, PGEN, GSL and FLDM among after-hours movers
Exagen (XGN) announces that all of its AVISE test offerings are now a contracted in-network service with Tufts Medical Center, an internationally-respected academic medical center."The incorporation of AVISE testing will play an important part in enabling rheumatologists’ ability to im...
SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vascul...
Exagen (XGN) moves up 1.98% after the autoimmune-related healthcare services company posts preliminary figures for FQ4 yesterday. Testing revenue to be $10.5-$10.8M (+10% to +13% Y/Y).However, the company holds back its SIMPONI revenue estimate due to the nature ...
Record Testing Revenue, Adopters and AVISE CTD ® Volumes SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported preliminary...
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the 2021 ICR Conference, which takes pl...
SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vascul...
Gainers: [[UUU]] +71.2%. [[IRIX]] +28.6%. [[XGN]] +10.6%. [[CANG]] +10.5%. [[MIRM]] +6.4%.Losers: [[ARCT]] -35.3%. [[ACY]] -23.3%. [[AIRT]] -8.8%. [[RHE]] -7.6%. [[RCMT]] -6.2%. For further details see: UUU, ACY, IRIX, and ARCT among after-hours movers
The following slide deck was published by Exagen Inc. in conjunction with this event. For further details see: Exagen (XGN) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...